TRUS Biopsy, MRI, and PROMIS Trial

Posted by Priya N. Werahera, PhD | Jun 2019

Priya N. Werahera, PhD, presented “TRUS Biopsy, MRI, and PROMIS Trial” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.

How to cite: Werahera, Priya N. “TRUS Biopsy, MRI, and PROMIS Trial”. January 26, 2019. Accessed Apr 2024. https://dev.grandroundsinurology.com/trus-biopsy-mri-and-promis-trial/

TRUS Biopsy, MRI, and PROMIS Trial

Priya N. Werahera, PhD, discusses the PROstate MR Imaging Study (PROMIS) trial and its implications for use in prostate cancer screening.

Summary:

Priya N. Werahera, PhD, discusses the PROstate MR Imaging Study (PROMIS) trial, which investigated whether multi-parametric (MP)-MRI can discriminate between men with and without clinically-significant prostate cancer who are at risk prior to first biopsy. Results showed mpMRI performed better than expected in a multicenter setting when used across 11 centers and by over a dozen radiologists. Dr. Werahera also discusses several limitations of the PROMIS trial as well as assessing the utility of biomarkers to identify men with clinically significant prostate cancer.

About the International Prostate Cancer Update

The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Werahera presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.

About The Author

Priya N. Werahera, PhD

Priya N. Werahera, PhD, is a Research Assistant Professor in the Departments of Pathology and Bioengineering at the University of Colorado Anschutz Medical Campus. He received his PhD in Electrical and Computer Engineering in 1994. His main research interests are biomedical imaging, optical spectroscopy, bioinstrumentation, computer modeling, and nanotechnologies for cancer diagnostics and therapeutics. Dr. Werahera is a renowned leader in clinical translational research in prostate cancer diagnosis and therapy with over 20 years of experience. He developed a novel computer algorithm and methodology to create equivalent 3D computer models of human prostate specimens. One of his major accomplishments is the proof-of-concept work on template-guided transperineal mapping biopsy protocol to identify low-risk prostate cancer patients. He led the team of investigators that measured prostate tumor growth rates in humans to find out whether there is a difference in growth rates of latent versus aggressive prostate cancer. He proved that maximum tumor doubling times of latent and prostate tumors are not significantly different, as was previously thought. Dr. Werahera has prototyped a minimally invasive 16g optical biopsy needle capable of diagnosing prostate cancer with very high sensitivity and specificity by inserting an optical sensor at the tip of a biopsy needle (US patent). Dr. Werahera is a Co-Founder of Precision Biopsy Inc. Dr. Werahera has written 60+ peer-reviewed journal and conference publications. He is a Member of the University of Colorado Cancer Center and a Senior Member of the Institution of Electrical and Electronics Engineers (IEEE).

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Exercise & Wellness

Share This